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Background: Patients undergoing surgery or chemotherapy often experience nausea and vomiting. To increase
their quality of life and treatment satisfaction, antiemetic medication, such as serotonin receptor antagonists, is
often prescribed for patients experiencing these symptoms. However, early warning signs suggest that serotonin
receptor antagonists can cause harm, including arrhythmia. Our objective is to identify the most effective
interventions that mitigate the risk of adverse cardiac events associated with serotonin receptor antagonists in
patients undergoing surgery and chemotherapy through a systematic review and network meta-analysis.
Methods/design: We will search electronic databases (for example, MEDLINE, Embase) from inception onwards, as
well as dissertations and governmental reports, to identify interventions (for example, telemetry,
electrocardiography, electrolyte monitoring) that decrease the cardiac risk associated with serotonin receptor
antagonists among surgery and chemotherapy patients. Eligible comparators include placebo or supportive care;
eligible study designs are experimental studies (randomized controlled trials (RCTs), quasi-RCTs, non-RCTs),
non-experimental studies (interrupted time series, controlled before-and-after studies), and cohort studies.
Outcomes of interest include arrhythmia, sudden cardiac death, QT prolongation, PR prolongation, and all-cause
mortality. We will include unpublished studies and studies published in languages other than English.
Draft inclusion and exclusion criteria will be established and pilot tested amongst the team. Subsequently, two
team members will screen the results in duplicate and resolve conflicts through discussion. The same process will
be followed to screen full-text articles, data abstraction, and appraise quality or risk of bias. To determine validity of
results, experimental and quasi-experimental studies will be assessed using the Cochrane Effective Practice and
Organisation of Care (EPOC) Risk of Bias tool, while cohort studies will be appraised using the Newcastle-Ottawa
Scale. We anticipate sufficient data and homogeneity to conduct random effects meta-analysis and network or
mixed treatment comparisons meta-analysis, if appropriate.
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Discussion: Our results will provide information regarding the utility of different strategies that can be used to mitigate
cardiac risk amongst patients taking serotonin antagonist receptors. Such results are likely to be of use to clinicians
prescribing these agents, as well as policy makers responsible for making decisions about antiemetic medications.
Trial registration: PROSPERO registry number: CRD42013003565Background
Many patients undergoing chemotherapy or surgery ex-
perience nausea and vomiting [1,2]. These symptoms are
not only distressing to patients, but may cause adverse
events, such as an increased length of hospitalization
[3], pulmonary complications, and wound dehiscence
[4]. To prevent these symptoms, many patients are pre-
scribed serotonin (5-HT3) receptor antagonists.
Serotonin receptor antagonists are powerful antiemetic
medications that inhibit nerves in the gastrointestinal tract,
blocking the emetic reflex [5]. Ondansetron (brand name
Zofran), dolasetron (brand names Anzemet, Anemet), and
granisetron (brand names Sancuso, Kytril, Kevatril) are
first-generation 5-HT3 receptor antagonists, while palono-
setron (brand names Aloxi, Alexi) is a second-generation
receptor antagonist [6].
Although 5-HT3 receptor antagonists are effective for
preventing nausea and vomiting among patients under-
going chemotherapy or surgery [1,7-9], early warning signs
suggest that these agents might cause cardiac harm. For
example, two studies examining chemotherapy among
children found that 5-HT3 induced prolongation of the
QT interval [10,11]. In the first study, the QT interval was
increased up to 24 hours after the antiemetic was given,
but this was asymptomatic and serious arrhythmias were
not noted [10]. In the second study, a similar transient in-
crease in the QT interval was observed, but was not found
to be clinically significant [11]. In this study, the prolonged
QT interval was associated with the 5-HT3 receptor an-
tagonist granisetron but not with ondansetron [11]. The
relationship between 5-HT3 receptor antagonists and car-
diac risk has not been confirmed by systematic review.
As a result of these concerns, regulatory actions have
been taken against these agents in some countries. For
example, dolasetron is contraindicated for any use in
children and for postoperative nausea and vomiting in
adults in Canada [12]. If this association is found to be
valid, it might be important to consider interventions
that might mitigate this risk.
Several diagnostic tests exist for monitoring or mitigat-
ing cardiac risk. These include electrocardiography, elec-
trolyte monitoring and replacement, and adjustment of
concomitant antiarrhythmics. Electrocardiography can be
employed after surgery or post-chemotherapy and pro-
vides information on PR prolongation, which might be in-
dicative of arrhythmic events and all-cause mortality [13].Electrocardiography can also detect QT prolongation,
which has been associated with arrhythmic events, includ-
ing torsades de pointes tachycardia [14], and sudden death
[15]. Continuous electrocardiography (>24 hours) can
be achieved using a cardiac telemetry monitor [16]. Im-
balance in electrolytes, including hypokalemia, hypo-
magnesemia, and hypocalcemia, might lead to QT interval
prolongation, suggesting the implementation of electro-
cardiography [17]. Finally, the use of antiarrhythmics
among patients with cardiac abnormalities [18] might be a
viable option for patients administered 5-HT3 receptor
antagonists who experience cardiac harm.
These interventions can be implemented amongst pa-
tients administered 5-HT3 receptor antagonists for nau-
sea and vomiting. However, such interventions would
inflict cost to the system and burden to patients. Our
objective is to determine whether interventions can be
implemented to mitigate the risk of adverse cardiac events
associated with 5-HT3 receptor antagonists amongst sur-
gery and chemotherapy patients through a systematic re-
view and network meta-analysis. This ‘query’ was posted
by policy makers in Canada, and our results will inform
their decision making for these agents.
Methods/design
Our systematic review protocol was compiled, reviewed by
the team, and peer reviewed by systematic review method-
ologists and pharmacoepidemiologists. It was then regis-
tered with the PROSPERO database (CRD42013003565).
The reporting of our review is based on guidance from
the Preferred Reporting Items for Systematic reviews
and Meta-analyses Protocols (PRISMA-P) [19]. We have
submitted a protocol to a complementary review on this
topic to Systematic Reviews (Tricco et al., personal com-
munication). Therefore, the methods will only be described
briefly here.
Eligibility criteria
Our eligibility criteria will be based on the PICOS criteria
(patients, interventions, comparators, outcomes, study de-
signs), outlined in Additional file 1:
 Patients: studies of patients of all ages receiving 5-
HT3 antagonist receptors for nausea and vomiting
symptoms post-surgery or after chemotherapy will
be included. Studies on all forms of chemotherapy
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are chemotherapy-naïve or have received
chemotherapy previously.
 Interventions: strategies to mitigate cardiac risk
amongst these patients, such as electrocardiography,
telemetry, adjustment of antiarrhythmics, and
electrolyte monitoring and replacement, will be
included.
 Comparators: placebo or supportive care will be
eligible comparators.
 Outcomes: the primary outcome is arrhythmia and
secondary outcomes are sudden death, QT
prolongation, PR prolongation, all-cause mortality,
nausea, and vomiting.
 Study designs: we will include experimental studies
(randomized controlled trials (RCTs), quasi-RCTs,
non-RCTs), quasi-experimental studies (interrupted
time series, controlled before-and-after studies), and
cohort studies.
 Other limitations: study inclusion will not be limited
by publication status, language of dissemination,
duration of follow-up, or period of study conduct.
Information sources and literature search
To identify relevant literature, we will search MEDLINE,
Embase, and Cochrane Central from inception onwards.
The electronic literature search will be supplemented by
searching for unpublished and difficult-to-locate material
[20], such as public health websites, trial registers, and
guideline producer websites. We will also scan the refer-
ences of included studies, contact 5-HT3 manufacturers,
and contact prolific authors in the field.
An experienced librarian will draft the search strategies.
This will subsequently be peer reviewed by another expert
librarian using the Peer Review of Electronic Search Strat-
egies (PRESS) checklist [21]. The draft literature search
for the main search strategy has been presented in a
protocol of a complementary review on this topic (Tricco
et al., personal communication).
Study selection process
A calibration exercise will be conducted by the team using
the draft eligibility criteria on a random sample of 50 titles
and abstracts from the literature search. The eligibility cri-
teria will be revised, as necessary. Subsequently, two team
members will screen the citations in duplicate. Conflicts
will be resolved by team discussion. The same process will
be followed for full-text screening.
Data items and data collection process
Following a similar process to screening the citations,
two team members will abstract the following data in
duplicate:1. Study characteristics, such as setting, country where
the study was conducted, details on the 5-HT3
medications, comparator used, and type of test
conducted to assess cardiac risk.
2. Patient characteristics, such as mean age, percent
women, type of surgery, and type of cancer.
3. Outcome results, such as number of patients
experiencing arrhythmia, and mean and standard
deviation for PR prolongation.
We will ensure that companion reports are sorted and
will contact authors for data clarification.
Methodological quality and risk of bias appraisal
Studies will be assessed using study-design specific tools.
Experimental and quasi-experimental studies will be ap-
praised using the Cochrane Effective Practice and Or-
ganisation of Care (EPOC) Risk of Bias Tool [22], while
cohort studies will be assessed using the Newcastle-
Ottawa Scale [23]. Lastly, publication bias will be visually
assessed using funnel plots [24].
Synthesis of included studies
First, we will describe our results from the data obtained
through our data abstraction. Second, we will attempt to
conduct a meta-analysis using a random effects model
[25] in SAS Version 9.2 [25]. Meta-regression analysis will
be conducted if the data are homogeneous, as per an I2
statistic of at least 60% [26]. Studies will be analyzed sep-
arately by age group (children versus adults) and patient
population (surgery versus chemotherapy). Third, network
meta-analysis will be conducted in WinBUGS [27], if fea-
sible. Consistency of results will be conducted by compar-
ing the results of our frequentist meta-analysis with those
obtained from the network meta-analysis, using methods
described elsewhere [28,29]. Sensitivity analysis will be
conducted to explore the effect of risk of bias and quality
(for example, low versus high risk of bias), attrition rates
(for example, low versus high attrition), 5-HT3 dosage
and formulations, inclusion of quasi-experimental and co-
hort studies, and priors used in the Bayesian meta-analysis
[30] on our results.
Discussion
This is the first systematic review that we are aware of
to focus specifically on strategies to mitigate cardiac risk
amongst patients undergoing surgery or chemotherapy
who are administered 5-HT3 receptor antagonists. If ef-
fective interventions exist, patients, clinicians, and policy
makers will have to weigh the pros and cons of using 5-
HT3 medication. For example, some patients might wish
to forgo the use of these antiemetic medications if they
are informed that this might lead to ongoing monitoring,
or perhaps patients who are already at risk of cardiac
Tricco et al. Systematic Reviews 2013, 2:45 Page 4 of 5
http://www.systematicreviewsjournal.com/content/2/1/45harm should not be prescribed 5-HT3 antagonist receptors.
However, patients will not be fully informed about this until
the utility of these mitigation strategies is determined.
We will use numerous strategies to diffuse our research
results. Examples include conference presentations, open
access journal publications, user-friendly executive sum-
maries, and dissemination meetings with patients, health-
care providers, and policy makers. We will also consider
dissemination through social media tools, such as Twitter
and facebook.
Additional file
Additional file 1: Draft Eligibility Criteria.
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